Anúncio
Anúncio

DXCM

DXCM logo

DexCom, Inc.

70.10
USD
Patrocinado
+0.21
+0.29%
07 de jan., 16:00 UTC -5
Encerrado
exchange

Pós-Mercado

70.52

+0.42
+0.60%

Relatórios de Lucros DXCM

Rácio de surpresa positiva

DXCM separação 31 de 40 últimas estimativas.

78%

Próximo Relatório

Data do Próximo Relatório
05 de fev. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$1.27B
/
$0.66
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+4.68%
/
+8.20%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+13.69%
/
+46.67%

DexCom, Inc. earnings per share and revenue

On 30 de out. de 2025, DXCM reported earnings of 0.61 USD per share (EPS) for Q3 25, beating the estimate of 0.57 USD, resulting in a 5.32% surprise. Revenue reached 1.21 bilhão, compared to an expected 1.20 bilhão, with a 0.57% difference. The market reacted with a -14.63% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 28 analistas forecast an EPS of 0.66 USD, with revenue projected to reach 1.27 bilhão USD, implying an aumentar of 8.20% EPS, and aumentar of 4.68% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
AngioDynamics, Inc.
Report Date
06 de jan. de 2026 Para Q2 26
Estimativa
-$0.10
Real
$0.00
Surpresa
+100.00%
FAQ
For Q3 2025, DexCom, Inc. reported EPS of $0.61, beating estimates by 5.32%, and revenue of $1.21B, 0.57% above expectations.
The stock price moved down -14.63%, changed from $68.20 before the earnings release to $58.22 the day after.
The next earning report is scheduled for 05 de fev. de 2026.
Based on 28 analistas, DexCom, Inc. is expected to report EPS of $0.66 and revenue of $1.27B for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio